3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
2
Phase 1
2
Status
Completed
2
Sponsor Class
NETWORK
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
133
Recurrence
33
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Neoplasms, Plasma Cell
15
Neoplasms
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia
7
Immunoglobulin Light-chain Amyloidosis
7
Lymphoma, Non-Hodgkin
6
Amyloidosis
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Hematologic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Burkitt Lymphoma
5
Paraproteinemias
4
Lymphoma, Mantle-Cell
4
Leukemia, Myeloid, Acute
4
Hematologic Diseases
4
Blood Protein Disorders
4
Neoplasm Metastasis
3
Myelodysplastic Syndromes
3
Lymphoma, B-Cell
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Corneal Diseases
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Interventions
carfilzomib
2
Dexamethasone
2
Cyclophosphamide
2
tivozanib
1
tislelizumab
1
pembrolizumab
1
neratinib
1
Nivolumab
1
Interleukin-15
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Cisplatin
1
Capecitabine
1
Calcium Dobesilate
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Disease
×
Dexamethasone
×
Clear all
NCT01857115
2024-11-13
wCCyd
European Myeloma Network B.V.
Phase 1/2
Completed
63 enrolled
NCT02204241
2023-07-03
CCD
European Myeloma Network B.V.
Phase 1/2
Completed
36 enrolled